Phase II Study of Cetuximab (Erbitux) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-Line Chemotherapy.

Trial Profile

Phase II Study of Cetuximab (Erbitux) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-Line Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Dec 2009

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms EFFI; STAGE
  • Most Recent Events

    • 25 Dec 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top